BioCentury
ARTICLE | Clinical News

Emricasan: Phase II data

March 30, 2015 7:00 AM UTC

Top-line data from a double-blind, U.S. Phase II trial in 38 patients with NAFLD, including patients with non-alcoholic steatohepatitis (NASH), showed that twice-daily 25 mg emricasan met the primary ...